Viscosupplementation Market Worth $7.8 Billion By 2027

The global viscosupplementation market size is expected to reach USD 7.8 billion by 2027, based on a new report published by Grand View Research, Inc. It is anticipated to exhibit a CAGR of 9.2% during the forecast period. Improving regulatory and reimbursement scenarios regarding the use of viscosupplements for the treatment of Osteoarthritis (OA) is expected to aid the growth. For instance, in U.S., unique reimbursement codes are allocated for different products available in the country.

Viscosupplementation procedure is an effective alternative for patients nonresponsive to other treatment options for osteoarthritis. These products have been clinically proven to be effective in providing long-term relief to OA patients with very few side-effects. Factors, such as the growing awareness regarding effective non-surgical procedures for the management of OA and global increase in the target population due to the increasing prevalence of obesity and other lifestyle-induced disorders, are expected to propel the market growth during the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/viscosupplementation-market

Further key findings from the study suggest:

Three injections segment dominated the market in 2019 owing to the availability of multiple products and significant market presence
Single injection segment is anticipated to witness the fastest growth during the forecast period owing to the increase in demand for a shorter regimen of procedures and faster recovery time
The utilization of viscosupplementation is maximum in Ambulatory Surgical Centers (ASCs), and orthopedic clinics. The higher usage of the viscosupplements is observed to be in outpatient settings owing to better reimbursement options
General physicians, rheumatologists, and orthopedists are the main influencer in the viscosupplementation market. The role of an influencer in the procurement of the product in the hospitals and clinics varies from region to region
Asia Pacific held the largest market share in 2019 and is expected to maintain its position during the forecast period due to the presence of key players and high incidence of osteoarthritis in the countries such as Japan and China.
Europe is expected to witness a lucrative CAGR in the forthcoming years, due to growing awareness about applications of non-surgical techniques and increasing disposable income
Key players are investing in improving their product portfolio to develop advanced products to maintain their market position. For instance, in March 2019, Seikagaku Corporation introduced a new intra-articular viscosupplement named HyLink (single injection) in Italy for the treatment of knee OA
Companies are also undertaking strategic initiatives, such as marketing licensing and distribution partnerships to increase geographic presence
Some key industry contributors are Anika Therapeutics, Inc.; Sanofi; Ferring B.V.; Seikagaku Corporation; Bioventus; Zimmer Holdings Inc; LG Life Sciences Ltd; and Lifecore Biomedical, LLC

Spirometer Market Size Worth $1.7 Billion By 2027

The global spirometer market size is expected to reach USD 1.7 billion in 2027, according to a new report by Grand View Research, Inc. The market is expected to expanding at a CAGR of 9.7% from 2020 to 2027. The prevalence of chronic respiratory diseases is rising among adults as well as children across the globe. The guidelines for the diagnosis and treatment of asthma in children and the Global Initiative on Asthma (GINA) guidelines recommend the usage of spirometry more frequently for asthma. GINA published a 2020 update for Global Strategy for Asthma Management and Prevention, which includes information about asthma after reviewing the scientific literature and contains citations from the scientific literature.

Technological advancements are leading to the development of innovative spirometers. Manufacturers are involved in the launch of technologically advanced products. For instance, in March 2018, a Swedish startup, NuvoAir, launched a handheld spirometer called Air Next. These palm-size spirometers are specially designed for home use and use Bluetooth wireless technology.

Amid the COVID-19 pandemic, manufacturers are witnessing a boost in product demand from healthcare professionals as well as patients to monitor their lung functions at home. Technologically advanced respiratory health management companies have developed digital spirometers that enable patients to easily monitor their lung function. For instance, in April 2020, Aluna, a San Francisco-based company, launched its FDA-approved portable digital spirometer, helping patients monitor their lung health at home.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/spirometer-market

Further key findings from the study suggest:

Table top spirometers dominated the type segment in terms of revenue share in the year 2019 as the device is widely used in the diagnosis of obstructive airway disorders
Desktop spirometers are likely to witness the fastest growth over the forecast period as the computer-based spirometry supports in making enhanced clinical decisions based on integrated clinical information
The flow measurement technology segment dominated the market in terms of revenue share in 2019 due to extensive use in pulmonary function testing. Peak flow measurement spirometers are expected to register the fastest growth over the forecast period
Based on application, Chronic Obstructive Pulmonary Disease (COPD) held the majority of the market share in 2019 pertaining to the high prevalence of mild to severe COPD. Whereas the asthma segment is expected to grow at the fastest rate during the forecast period due to the increasing prevalence of the disease and high treatment cost
In the end-use segment, hospitals and clinics held the largest market share in 2019 due to the extensive use of spirometry for diagnosis and monitoring of chronic respiratory disorders. However, the home healthcare segment is likely to experience an impressive growth rate in the coming years due to the adoption of telemedicine and the launch of new products
North America dominated the market in terms of revenue share in 2019 due to the high prevalence of COPD in the U.S. On the other hand, in the Asia Pacific, the market is expected to showcase the fastest growth rate due to the improving primary care initiatives for early diagnosis and management of chronic lung diseases such as asthma and COPD

Veterinary Surgical Instrument Market Size Worth $1.5 Billion By 2027

The global veterinary surgical instrument market size is expected to reach USD 1.5 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 7.0% from 2020 to 2027. Growing demand for pet adoption is expected to drive the market over the forecast period. Increasing income in developing countries is another driving factor. For instance, according to a report by the American Veterinary Medical Association (AVMA) in 2017, around 46.0% of households had multiple types of pets in the U.S. Furthermore, key players are implementing newer strategies to sustain in this competitive market. For instance, in March 2019, Bruhat Bengaluru Mahanagara Palike (BBMP) in India planned to introduce a rescue ambulance to rescue injured animals for faster treatment. The ambulance will be equipped with all the necessary tools such as surgical instruments and sterilizers.

Moreover, technological advancements in surgical devices and the availability of a number of detection techniques are anticipated to create growth opportunities in the market. These include microfracture detection, laparoscopy, and 3D printing. For instance, in October 2017, Surgical Holdings launched two new product-chisels and osteotomes-to expand its product portfolio.

The global veterinary surgical instrument market is highly competitive in nature. It is dominated by participants such as B. Braun Vet Care GmbH, Medtronic, Jorgen Kruuse A/S, and SurgiVet. Market players focus on adopting strategies such as new product launches, partnerships, and collaborations. For instance, in July 2018, B. Braun Vet Care signed an agreement to deal with CP Medical wherein the company will distribute B. Braun’s veterinary Infusion Therapy product line in the U.S. and Canada.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/veterinary-surgical-instruments-market

Further key findings from the report suggest:

An increasing number of veterinary practitioners are anticipated to create growth opportunities in the market
Handheld devices accounted for the largest share in 2019, owing to their use for multiple purposes and ease of handling
The small animal segment is expected to exhibit lucrative growth over the forecast period owing to rising incidences of pet adoption and increased demand for efficient care
The dental surgery segment held the largest share in 2019 due to the increasing prevalence of periodontal diseases and rising demand for pet dental care
North America dominated the global market in 2019 due to favorable pet insurance policies and new product launches by companies. However, Asia Pacific is anticipated to exhibit the most lucrative growth rate over the forecast period owing to the rising demand for pet adoption and increasing disposable income, particularly in Japan and India
Some of the key companies in the market are Medtronic, DRE Veterinary, B. Braun Vet Care GmbH, and Jorgen Kruuse A/S.

Women’s Health Market Size Worth $47.8 Billion By 2027

The global women’s health market size is expected to reach USD 47.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 4.9% over the forecast period. Governments and various private organizations focused on women health across the globe, which is likely to drive the market in the coming years. Coverage plans provided to women is one of the key factors expected to drive the market in developed countries.

In U.S., coverage plans provide preventive services for women without any copayment charges. This includes anemia screening on a routine basis, folic acid supplements for women who may become pregnant, hepatitis B screening, breast cancer screening, and contraception. Healthy People 2020 was established by the Department of Health and Human Services which has a 10-year agenda for improving the health of all Americans.

Initiatives undertaken by countries such as India, Japan, China, Singapore, and Australia are expected to drive the market over the forecast period. For example, in September 2016, Australia’s Ministry of Health provided a grant of USD 3.8 million till 2019 to Jean Hailes, a women’s health group, to help develop its education and outreach.

Owing to aging and rising incidences of obesity, an increase in prevalence of osteoarthritis (OA) has been witnessed. According to the United Nations, about 10%-15% of all adults aged over 60 have some degree of OA, and the condition is more prevalent in women. According to the CDC, in 2013, back problems were more common in women (30.2%). According to the International Osteoporosis Foundation (IOF), the worldwide prevalence of osteoporosis among women was over 200.0 million in 1990, which is anticipated to reach 680.0 million by 2050.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/womens-health-market

Further key findings from the study suggest:

On the basis of application, the women’s health market is segmented into postmenopausal osteoporosis, endometriosis, hormonal infertility, contraceptives, and polycystic ovary syndrome (PCOS) and menopause. Contraceptives held a majority of the market share in terms of revenue in 2019
Availability of a wide range of drugs for the treatment of postmenopausal osteoporosis is projected to boost the market. These include Fosamax, Actonel, Boniva, Reclast, Evista, and Prolia. In April 2017, the U.S. FDA approved a new drug, Tymlos, to treat postmenopausal osteoporosis. The approval was based on data of an 18-month trial that demonstrated a substantial reduction in the risk of vertebral and non-vertebral fractures
North America held the largest market share in 2019 owing to technological advancements and presence of major market players in the region. Asia Pacific, on the other hand, is expected to witness the highest growth rate over the forecast period
Some of the key players in the women’s health market are Bayer AG; Allergan; Merck & Co., Inc.; Teva Pharmaceuticals; Pfizer; Agile Therapeutics; Amgen, Inc.; AstraZeneca, Bristol-Myers Squibb, and Ferring B.V.

Cord Blood Banking Services Market Size Worth $82.3 Billion By 2025

The global cord blood banking services market is expected to reach over USD 82.3 billion by 2025, growing at an estimated CAGR of around 11.9% from 2017 to 2025, according to a new study by Grand View Research, Inc. Key drivers of the market include increasing application of stem cell therapies in disease treatment, and rising prevalence of life threatening genetic disorders.

Moreover, increasing spending capacity is fueling the demand for advanced healthcare facilities including disease prevention and treatment. As a result, parents are increasingly demanding CBB services to ensure safety of their child’s future. Furthermore, private players are practicing marketing activities which are creating awareness about the availability of the CBB services and their benefits.

In addition, governments worldwide are promoting public CBB to develop ethnically diverse cord blood repository which would increase the chances of finding suitable human leukocyte antigen (HLA) match for the patients. As a result, availability of the ethnically rich CB repository coupled with anticipated rise in the stem cell therapies and bone marrow transplants, is expected to spur the CBB services during the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cord-blood-banking-services-market

Further Key Findings From the Report Suggest:

Private bank segment accounted for the largest revenue share in 2016. High cost of collection, processing, and storage along with the maximum awareness created by marketing activities practiced by the players resulted in large revenue share of private banks across the globe.
Rising government support and no storage and collection costs are the major factors anticipated to drive the public banking sector during the forecast period from 2017 to 2025 with highest CAGR.
North America dominated the global market and was followed by Europe in 2016. Dominance of North America is owing to government support and high rate of stem cell therapy in the U.S. and Canada.
Moreover, high awareness and insurance coverage of cord blood banking and stem cell therapies is further boosting the growth of the market in North America
Densely populated emerging countries of Asia Pacific are anticipated to show significant growth during the forecast period from 2017 to 2025.
Factors such as increasing investment by global players, government support and rising healthcare expenditure are anticipated to boost the cord blood banking services market in Asia Pacific
Global CBB services sector is highly fragmented with presence of many private and public players. Few global players operate in various geographies through subsidiaries. While local players are operating independently in respective geographies.
Key players of this market include China Cord Blood Corporation, Cord Blood America, Inc., CBR Systems, Inc., Cordlife Group Limited, Cryo-Cell International, Inc., Cryo-Save AG, Lifeforce Cryobanks, National Cord Blood Program, ViaCord, Inc. and Virgin Health Bank

Protein Expression Market Worth $3.0 Billion By 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies, and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/protein-expression-market

Further Key Findings From The Report Suggest:

Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase for therapeutic, industrial, and research applications
The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India
Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.

Cancer Stem Cells Market Worth $1.6 Billion By 2025

The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.

Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.

Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cancer-stem-cells-market

Further key findings from the report suggest:

The anti-CSC therapeutics segment accounted for a significant share owing to increasing R&D activities for the development of novel therapeutics
Anti-CSCs therapeutics/agents include agents that target key pathways, surface markers, immuno-evasion & tumor microenvironment, along with nanoparticle-based therapies. As key pathways play a major role in tumor regulation, pathway inhibitors captured the largest share owing to the presence of a broad portfolio of products under pipeline
With rising prevalence of bladder cancer, the segment is expected to exhibit the highest CAGR of 10.47% during the forecast period
North America held the largest share in 2016 owing to presence of a large number of facilities in the U.S. that offer stem cell services
Asia Pacific is likely to emerge as the fastest growing regional market owing to increasing investments by various agencies to accelerate research activities in Asian countries
Some of the prominent players in the market are Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; and Lonza.

Pancreatic Cancer Treatment Market Size Worth $4.2 Billion By 2025

The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.

According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market

Further key findings from the study suggest:

The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.

Pacemaker Market Size Worth $5.8 Billion By 2027

The global pacemaker market size is anticipated to reach USD 5.8 billion by 2027, expanding at a CAGR of 2.9%, as per the new report by Grand View Research, Inc. The increasing prevalence of cardiovascular diseases is a key growth driver for the market. As per the CDC, in 2017, CVDs accounted for about 800,000 deaths in the U.S alone. Moreover, coronary heart disease accounts for the highest number of deaths, followed by stroke and heart failure.

As per the British Heart Foundation Centre in 2018, nearly 7.4 million individuals are living with circulatory and heart diseases in the UK. More than 43,000 individual under 75 years of age dies due to cardiac diseases every year in the UK. To curb the rising prevalence of CVDs is government bodies and key market players are channelizing revenues to offer a potential treatment. This is anticipated by the influx of advanced products in this market space.

As per the CDC, 2020, more than 15.0% of U.S. adults are physically inactive that shows the prevalence of adult physical inactivity. Technological developments are quickly renovating the market. Key players are focusing on expanding their current portfolio such as in January 2020, BIOTRONIK launched an injectable cardiac monitor, BIOMONITOR III in Japan. It is intended to measure irregular heart rhythms with increased clarity. The injectable cardiac monitor also documents the unexplained syncope. Moreover, in January 2019, Medtronic launched MyCareLink Heart (TM)-a mobile app for communicating directly with patients via smartphones.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pacemaker-market

Further key findings from the report suggest:

MRI compatible pacemakers is the fastest-growing segment from 2020 to 2027 owing toa higher patient preference rate as 75% of the patients with pacemakers are likely to get MRI during their lifetimes
Atrial Fibrillation held the largest market share in 2019 owing to the heightened prevalence of growing with age. As per the National Center for Biotechnology Information, 2020, nearly 6 to 12 million people globally are expected to suffer from atrial fibrillation in the US alone by 2050
The biventricular chamber product segment is expected to be the fastest-growing segment from 2020 to 2027. The device is also is known as Cardiac Resynchronization Therapy (CRT) device. An increase in the prevalence of heart failure is one of the major factors driving the growth of the segment
Key companies are adopting new strategies to attain a competitive edge. Product development, collaborations, partnerships, mergers and acquisitions, and regional expansion are few of them.

Tissue Diagnostics Market Worth $6.6 Billion By 2027

The global tissue diagnostics market size is anticipated to reach USD 6.6 billion by 2027, growing at a CAGR of 5.9% during the forecast period, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to the lack of skilled pathologists has driven the market. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplement market growth.

The digitalization of tissue diagnostic techniques has resulted in the improvement of workflows and better patient care. Ongoing strategic models taken-up by key companies to enhance the efficiency of diagnostics also drives the market. For instance, in December 2019, Philips collaborated with Paige to provide clinical-grade artificial intelligence-based solutions to pathology laboratories. This enhanced the speed and accuracy of cancer diagnostics in laboratories.

Tissue diagnostic techniques, such as immunohistochemistry (IHC) or in situ hybridization, are used in companion diagnostics (CDx) to determine the quantity of a target analyte present in the sample. Introduction of CDx tests, such as the launch of the VENTANA HER2 Dual ISH CDx

Click the link below:
https://www.grandviewresearch.com/industry-analysis/tissue-diagnostics-market

Further key findings from the report suggest:

IHC tests are highly adopted as these tests are specific and helpful in identifying the variations between different types of cancer, resulting in the largest revenue share
A rise in the investments for the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment with the fastest CAGR.
Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of breast cancer
Prostate cancer is anticipated to register lucrative growth owing to the extensive ongoing research pertaining to early diagnosis and prevention of this disease
Hospitals dominated the market in terms of revenue share due to the high adoption of tissue diagnostics solutions. These solutions provide accurate results in minimal time than conventional testing procedures
North America accounted for the largest revenue share owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
The requirement of better laboratory management systems, growing demand for novel patient care facilities, and favorable regulatory framework, boost the Asia Pacific market at a lucrative pace
Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the tissue diagnostics market
Key vendors are engaged in novel product developments, partnership, and acquisition models to maintain their revenue share in the market.